BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 29255924)

  • 1. Salvage radiotherapy in prostate cancer patients with biochemical relapse after radical prostatectomy : Prolongation of prostate-specific antigen doubling time in patients with subsequent biochemical progression.
    Lohm G; Neumann K; Budach V; Wiegel T; Hoecht S; Gollrad J
    Strahlenther Onkol; 2018 Apr; 194(4):325-332. PubMed ID: 29255924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy : Long-term follow-up of a single-center survey.
    Lohm G; Lütcke J; Jamil B; Höcht S; Neumann K; Hinkelbein W; Wiegel T; Bottke D
    Strahlenther Onkol; 2014 Aug; 190(8):727-31. PubMed ID: 24577132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy.
    Geinitz H; Riegel MG; Thamm R; Astner ST; Lewerenz C; Zimmermann F; Molls M; Nieder C
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1930-7. PubMed ID: 21514736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining biochemical recurrence after radical prostatectomy and timing of early salvage radiotherapy : Informing the debate.
    Budäus L; Schiffmann J; Graefen M; Huland H; Tennstedt P; Siegmann A; Böhmer D; Budach V; Bartkowiak D; Wiegel T
    Strahlenther Onkol; 2017 Sep; 193(9):692-699. PubMed ID: 28470414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy.
    Ward JF; Zincke H; Bergstralh EJ; Slezak JM; Blute ML
    J Urol; 2004 Dec; 172(6 Pt 1):2244-8. PubMed ID: 15538240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Larger maximum tumor diameter at radical prostatectomy is associated with increased biochemical failure, metastasis, and death from prostate cancer after salvage radiation for prostate cancer.
    Johnson SB; Hamstra DA; Jackson WC; Zhou J; Foster B; Foster C; Song Y; Li D; Palapattu GS; Kunju L; Mehra R; Sandler H; Feng FY
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):275-81. PubMed ID: 23886418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcomes of salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Lee EK; Mui WH; Chan AW; Tung Y; Wong FC
    Hong Kong Med J; 2018 Jun; 24(3):218-225. PubMed ID: 29807949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variables which might predict the response to salvage radiotherapy in chinese patients with biochemical failure after radical prostatectomy.
    Xu Y; Liu R; Zhang Z; Hao Q; Qi S; Li J; Teng Z
    Urol Int; 2006; 77(3):205-10. PubMed ID: 17033206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early salvage radiation therapy combined with short-term hormonal therapy in recurrent prostate cancer after radical prostatectomy: single-institution 4-year data on outcome, toxicity, health-related quality of life and co-morbidities from 184 consecutive patients treated with 70 Gy.
    Cortés-González JR; Castellanos E; Sandberg K; Eriksson MH; Wiklund P; Carlsson S; Cohn-Cedermark G; Harmenberg U; Gustafsson O; Levitt SH; Lennernäs B; Brandberg Y; Márquez M; Kälkner KM; Nilsson S
    Int J Oncol; 2013 Jan; 42(1):109-17. PubMed ID: 23151842
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series.
    Gandaglia G; Fossati N; Karnes RJ; Boorjian SA; Colicchia M; Bossi A; Seisen T; Cozzarini C; Di Muzio N; Noris Chiorda B; Zaffuto E; Wiegel T; Shariat SF; Goldner G; Joniau S; Battaglia A; Haustermans K; De Meerleer G; Fonteyne V; Ost P; Van Poppel H; Montorsi F; Briganti A
    Eur Urol; 2018 Apr; 73(4):512-518. PubMed ID: 29229176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elective pelvic versus prostate bed-only salvage radiotherapy following radical prostatectomy: A propensity score-matched analysis.
    Song C; Kang HC; Kim JS; Eom KY; Kim IA; Chung JB; Hong SK; Byun SS; Lee SE
    Strahlenther Onkol; 2015 Oct; 191(10):801-9. PubMed ID: 26159555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term Outcome of Prostate Cancer Patients Who Exhibit Biochemical Failure Despite Salvage Radiation Therapy After Radical Prostatectomy.
    Ying J; Wang CJ; Yan J; Liauw SL; Straka C; Pistenmaa D; Xie XJ; Lotan Y; Roehrborn C; Kim DN
    Am J Clin Oncol; 2017 Dec; 40(6):612-620. PubMed ID: 26165416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy.
    Stephenson AJ; Shariat SF; Zelefsky MJ; Kattan MW; Butler EB; Teh BS; Klein EA; Kupelian PA; Roehrborn CG; Pistenmaa DA; Pacholke HD; Liauw SL; Katz MS; Leibel SA; Scardino PT; Slawin KM
    JAMA; 2004 Mar; 291(11):1325-32. PubMed ID: 15026399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
    Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
    Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome--results of a retrospective study.
    Wiegel T; Lohm G; Bottke D; Höcht S; Miller K; Siegmann A; Schostak M; Neumann K; Hinkelbein W
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(4):1009-16. PubMed ID: 18963539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved biochemical outcome with adjuvant radiotherapy after radical prostatectomy for prostate cancer with poor pathologic features.
    Vargas C; Kestin LL; Weed DW; Krauss D; Vicini FA; Martinez AA
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(3):714-24. PubMed ID: 15708249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage radiotherapy for biochemical recurrence after radical prostatectomy: does the outcome depend on the prostate cancer characteristics?
    Viani GA; Hamamura AC; Correa AC; de Arruda FT
    Int Braz J Urol; 2019; 45(2):237-245. PubMed ID: 30676298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.